Skip to main content
Figure 1 | Malaria Journal

Figure 1

From: The story of artesunate–mefloquine (ASMQ), innovative partnerships in drug development: case study

Figure 1

International partners involved in the development of ASMQ FDC. FACT Core Members: DNDi, TDR of WHO, Farmanguinhos/Fiocruz (BR), Université Bordeaux Segalen (FR), Universiti Sains Malaysia (MY), Mahidol University (TH), Mahidol Oxford Tropical Medicine Research Unit, Shoklo Malaria Research Unit (TH), Centre National de Recherche et de la Formation sur le Paludisme (CNRFP) (BF), University of Oxford (UK). Preclinical Development: Universiti Sains Malaysia (MY), Farmanguinhos /Fiocruz (BR), Cipla Ltd (IN). Clinical Development: Southeast Asia: University of Oxford (UK), Mahidol University (TH), Mahidol Oxford Tropical Medicine Research Unit (TH), University Sains Malaysia (MY), Shoklo Malaria Research Unit (TH), Mae Sot Clinic (TH), Indian Council for Medical Research (IN), Médecins Sans Frontières, Medical Action Myanmar (MM); Latin America: Amazon Network for the Surveillance of Anti-malarial Drug Resistance (RAVEDRA)/Ministry of Health (BR), National Malaria Control Program Brazil; Africa: CNRFP (BF), Kenya Medical Research Institute (KEMRI) (KE), Institute of Tropical Medicine Anvers (BE), National Institute for Malaria Research (TZ), Kwame Nkrumah University (GH), Centre Muraz (BF), University of Malawi (MW), Tropical Medicines Research Centre (ZM), Royal Tropical Institute (KIT) (NL), Liverpool School of Tropical Medicine (UK), Ifakara Health Institute (TZ). Manufacturers: Farmanguinos/Fiocruz (BR), Cipla Ltd (IN).

Back to article page